1 |
Rugge M, Fassan M, Graham D. Epidemiology of gastric cancer. In: Strong VE, editor. Gastric Cancer: Principles and Practice. Cham: Springer, 2015:23-34.
|
2 |
Orditura M, Galizia G, Sforza V, Gambardella V, Fabozzi A, Laterza MM, et al. Treatment of gastric cancer. World J Gastroenterol 2014;20:1635-1649.
DOI
|
3 |
Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010:CD004064.
|
4 |
Kilic L, Ordu C, Yildiz I, Sen F, Keskin S, Ciftci R, et al. Current adjuvant treatment modalities for gastric cancer: from history to the future. World J Gastrointest Oncol 2016;8:439-449.
DOI
|
5 |
Fuentes E, Ahmad R, Hong TS, Clark JW, Kwak EL, Rattner DW, et al. Adjuvant therapy completion rates in patients with gastric cancer undergoing perioperative chemotherapy versus a surgery-first approach. J Gastrointest Surg 2016;20:172-179.
DOI
|
6 |
Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KW, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy CLASSIC: a phase 3 open-label, randomised controlled trial. Lancet 2012;379:315-321.
DOI
|
7 |
Diaz-Nieto R, Orti-Rodriguez R, Winslet M. Post-surgical chemotherapy versus surgery alone for resectable gastric cancer. Cochrane Database Syst Rev 2013:CD008415.
|
8 |
Lee JH, Kim JG, Jung HK, Kim JH, Jeong WK, Jeon TJ, et al. Clinical practice guidelines for gastric cancer in Korea: an evidence-based approach. J Gastric Cancer 2014;14:87-104.
|
9 |
Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy CLASSIC: 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol 2014;15:1389-1396.
DOI
|
10 |
Miceli R, Tomasello G, Bregni G, Di Bartolomeo M, Pietrantonio F. Adjuvant chemotherapy for gastric cancer: current evidence and future challenges. World J Gastroenterol 2014;20:4516-4525.
DOI
|
11 |
Japanese Gastric Cancer Association . Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer 2017;20:1-19.
|
12 |
Foo M, Leong T. Adjuvant therapy for gastric cancer: current and future directions. World J Gastroenterol 2014;20:13718-13727.
DOI
|
13 |
Takahari D, Hamaguchi T, Yoshimura K, Katai H, Ito S, Fuse N, et al. Survival analysis of adjuvant chemotherapy with S-1 plus cisplatin for stage III gastric cancer. Gastric Cancer 2014;17:383-386.
DOI
|
14 |
Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor REGATTA: a phase 3, randomised controlled trial. Lancet Oncol 2016;17:309-318.
DOI
|
15 |
Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011;29:4387-4393.
DOI
|
16 |
Zhao SL, Fang JY. The role of postoperative adjuvant chemotherapy following curative resection for gastric cancer: a meta-analysis. Cancer Invest 2008;26:317-325.
DOI
|
17 |
Allum WH, Blazeby JM, Griffin SM, Cunningham D, Jankowski JA, Wong R. Guidelines for the management of oesophageal and gastric cancer. Gut 2011;60:1449-1472.
DOI
|
18 |
Saif MW, Makrilia N, Zalonis A, Merikas M, Syrigos K. Gastric cancer in the elderly: an overview. Eur J Surg Oncol 2010;36:709-717.
DOI
|
19 |
Imamura H, Kishimoto T, Takiuchi H, Kimura Y, Morimoto T, Imano M, et al. Phase II study of S-1 monotherapy in patients over 75 years of age with advanced gastric cancer (OGSG0404). J Chemother 2014;26:57-61.
DOI
|
20 |
Eun H, Hur H, Byun CS, Son SY, Han SU, Cho YK. Effects of continuing adjuvant S-1 for 1 year on the prognosis of gastric cancer patients: results from a prospective single center study. J Gastric Cancer 2015;15:113-120.
DOI
|
21 |
Aoyama T, Yoshikawa T, Hayashi T, Kuwabara H, Mikayama Y, Ogata T, et al. Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for gastric cancer. Gastric Cancer 2013;16:133-139.
DOI
|
22 |
Aoyama T, Sato T, Maezawa Y, Kano K, Hayashi T, Yamada T, et al. Postoperative weight loss leads to poor survival through poor S-1 efficacy in patients with stage II/III gastric cancer. Int J Clin Oncol 2017;22:476-483.
DOI
|
23 |
Yamashita K, Kurokawa Y, Yamamoto K, Hirota M, Kawabata R, Mikami J, et al. Risk factors for poor compliance with adjuvant S-1 chemotherapy for gastric cancer: a multicenter retrospective study. Ann Surg Oncol 2017;24:2639-2645.
DOI
|
24 |
Di Costanzo F, Gasperoni S, Manzione L, Bisagni G, Labianca R, Bravi S, et al. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst 2008;100:388-398.
DOI
|
25 |
Morris M, Platell C, Fritschi L, Iacopetta B. Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients. Br J Cancer 2007;96:701-707.
|